Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer

BACKGROUND: Sipuleucel-T is a US Food and Drug Administration-approved autologous cellular immunotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We examined whether administering ipilimumab after sipuleucel-T could modify immune and/or clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Meenal, Zhang, Li, Subudhi, Sumit, Chen, Brandon, Marquez, Jaqueline, Liu, Eric V, Allaire, Kate, Cheung, Alexander, Ng, Sharon, Nguyen, Christopher, Friedlander, Terence W, Aggarwal, Rahul, Spitzer, Matthew, Allison, James P, Small, Eric J, Sharma, Padmanee, Fong, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126308/
https://www.ncbi.nlm.nih.gov/pubmed/33986125
http://dx.doi.org/10.1136/jitc-2020-002254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126308/
https://www.ncbi.nlm.nih.gov/pubmed/33986125
http://dx.doi.org/10.1136/jitc-2020-002254

Ejemplares similares